Cargando…
Cell-Mediated Release of Nanoparticles as a Preferential Option for Future Treatment of Melanoma
Targeted and immune therapies have unquestionably improved the prognosis of melanoma patients. However the treatment of this neoplasm still requires approaches with a higher therapeutic index, in order to reduce shortcomings related to toxic effects and aspecific targeting. This means developing the...
Autores principales: | Chillà, Anastasia, Margheri, Francesca, Biagioni, Alessio, Del Rosso, Tommaso, Fibbi, Gabriella, Del Rosso, Mario, Laurenzana, Anna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408438/ https://www.ncbi.nlm.nih.gov/pubmed/32630815 http://dx.doi.org/10.3390/cancers12071771 |
Ejemplares similares
-
Mature and progenitor endothelial cells perform angiogenesis also under protease inhibition: the amoeboid angiogenesis
por: Chillà, Anastasia, et al.
Publicado: (2018) -
Publisher Correction to: delivery systems of CRISPR/Cas9-based cancer gene therapy
por: Biagioni, Alessio, et al.
Publicado: (2019) -
uPAR Knockout Results in a Deep Glycolytic and OXPHOS Reprogramming in Melanoma and Colon Carcinoma Cell Lines
por: Biagioni, Alessio, et al.
Publicado: (2020) -
EGFR/uPAR interaction as druggable target to overcome vemurafenib acquired resistance in melanoma cells
por: Laurenzana, Anna, et al.
Publicado: (2019) -
Delivery systems of CRISPR/Cas9-based cancer gene therapy
por: Biagioni, Alessio, et al.
Publicado: (2018)